Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
RESEARCH TOOLSreports
BINV Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr22.70 - kr50.80
Previous CloseN/A
Volume47.26K
Average Volume (3M)64.80K
Market Cap
kr2.51B
Enterprise Valuekr1.90B
Total Cash (Recent Filing)kr742.21M
Total Debt (Recent Filing)kr15.19M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding65,804,360
10 Day Avg. Volume70,388
30 Day Avg. Volume64,800
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)3.06
Price to Sales (P/S)0.00
P/FCF Ratio-5.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr39.01Price Target Upside2.25% Upside
Rating ConsensusHold
Number of Analyst Covering0
BioInvent International AB News
PremiumCompany Announcements
BioInvent’s BI-1808 Shows Promising Results in Phase 2a CTCL Study
PremiumCompany Announcements
BioInvent Reports Positive Phase 1 Results for Cancer TherapyPremiumCompany Announcements
BioInvent Showcases BI-1910 Development at PAGE 2025PremiumCompany Announcements
BioInvent Sells Mezagitamab Rights to XOMA for $30 Million
PremiumCompany Announcements
BioInvent Reports Promising Phase 2a Results for BI-1808 in CTCL
PremiumCompany Announcements
BioInvent Reports Promising Phase 2a Data for NHL TreatmentPremiumCompany Announcements
BioInvent International AB: Q1 2025 Financial and Clinical Progress
PremiumCompany Announcements
BioInvent Reports 2024 Progress and FinancialsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr22.70 and its highest was kr50.80 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr2.51B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 26, 2025 which is in 37 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2025. The company reported -kr1.772 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.772.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.772 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.461%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
Company Description
BioInvent International AB
BioInvent International AB (BINV) is a biotechnology company based in Sweden, specializing in the discovery and development of novel immuno-modulatory antibodies for the treatment of cancer. The company operates in the biopharmaceutical sector and focuses on the development of its proprietary antibodies and immune-oncology therapies. BioInvent's core services include the research, development, and commercialization of drug candidates aimed at addressing unmet medical needs in oncology.
BINV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic collaborations, with promising data in lead compounds and strong financial reserves. However, these positives are counterbalanced by decreased net sales, increased operating costs, and significant financial losses.Read More>Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
SynAct Pharma AB
―